Amalgamated Financial’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

Amalgamated Financial’s Portfolio VBIV Stock Details VBIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$50K	Buy	+995	New	+$49.2K	﹤0.01%	2438

Other funds holding VBIV

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

GAI

General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Amalgamated Financial's VBIV Position: Q1 2022 in Review

Amalgamated Financial opened a new position in VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q1 2022: 995 shares worth $50K. The stake represents ﹤0.01% of the portfolio and ranks #2438 among its holdings.

131 funds tracked by Wall St. Rank hold VBIV as of Q1 2022.

Amalgamated Financial held 995 shares of VBI Vaccines, Inc. New Common Stock (Canada) worth $50K as of Q1 2022.
VBI Vaccines, Inc. New Common Stock (Canada) was a new Amalgamated Financial position in Q1 2022.
VBI Vaccines, Inc. New Common Stock (Canada) made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2438 holding.
131 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.